All In Biotech

Drug Trial Radar · NCT06536374

Folate Study in Men With Advanced Prostate Cancer

A Phase II, Open Label, Randomized Controlled Pilot Study Evaluating Trimethoprim in Patients Commencing Androgen Deprivation Therapy for Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
University of California, San DiegoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The researchers hope to learn if Trimethoprim, 150mg taken daily for 3 months, is a safe and effective way to reduce folate levels at time of Androgen Deprivation Therapy (ADT) in men with advanced prostate cancer. This study will help find out what effects, good and/or bad, this drug has on people who take it and on its effect on the disease. The safety of this drug in humans has been tested in prior research studies; however, some side effects may not yet be known.

Conditions

  • Prostate Cancer

Interventions

  • Trimethoprim TabletsDrug

    Trimethoprim 150mg is administered once daily for 3 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of TrimethoprimTime frame: From first dose of study therapy through 1 month after completion of study therapy.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California, San Diego

    La Jolla, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.